US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
0.8112
+0.0051 (+0.63%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 23, 2026
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 08, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 04, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 06, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 30, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Announces Up To $6 Million Private Placement
March 23, 2026
$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
March 11, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 25, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
February 11, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
February 04, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
January 20, 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
November 26, 2025
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
November 25, 2025
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
November 19, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
November 05, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
June 30, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
June 11, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
June 05, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
